Laura C. Collins
YOU?
Author Swipe
View article: Individual- and Neighborhood-Level Predictors of HIV Care Continuum Progression: Clark County, Nevada
Individual- and Neighborhood-Level Predictors of HIV Care Continuum Progression: Clark County, Nevada Open
Background As the US human immunodeficiency virus (HIV) epidemic is disproportionately affecting underserved communities, it is critically important to investigate how social determinants of health affect diagnosis, treatment, and preventi…
View article: Malignant phyllodes tumours of the breast: the case for revising <scp>WHO’</scp>s ‘full house’ diagnostic criteria
Malignant phyllodes tumours of the breast: the case for revising <span>WHO’</span>s ‘full house’ diagnostic criteria Open
Phyllodes tumours (PTs) of the breast present diagnostic challenges due to their complex histological features and potential for malignant behaviour. The World Health Organisation (WHO) classification requires the presence of five adverse …
View article: Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer Open
Uveal melanoma (UM) is the most common intraocular cancer in adults, with metastatic disease (mUM) occurring in approximately half of the patients. Tebentafusp, an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC), is a …
View article: Helping ourselves, helping others: the Young Women’s Breast Cancer Study (YWS) – a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger
Helping ourselves, helping others: the Young Women’s Breast Cancer Study (YWS) – a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger Open
Purpose Compared with older women diagnosed with breast cancer, younger women are more likely to die of breast cancer and more likely to suffer psychosocially in both the short-term and long term. The Young Women’s Breast Cancer Study (YWS…
View article: Second Primary Breast Cancer in Young Breast Cancer Survivors
Second Primary Breast Cancer in Young Breast Cancer Survivors Open
Importance Among women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher than that of women who are older when they develop a first primary…
View article: High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer–testis antigen PRAME
High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer–testis antigen PRAME Open
Background PRAME (Preferentially expressed Antigen in Melanoma) is a cancer–testis antigen expressed in several tumor indications, representing an attractive anticancer target. However, its intracellular location limits targeting by tradit…
View article: Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression
Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression Open
Immune escape is a prerequisite for tumor growth. We previously described a decline in intratumor activated cytotoxic T cells and T cell receptor (TCR) clonotype diversity in invasive breast carcinomas compared to ductal carcinoma in situ …
View article: 1108 Novel regulators of ImmTAC-mediated killing of melanoma cancer cells revealed by genome-wide CRISPR-Cas9 screens
1108 Novel regulators of ImmTAC-mediated killing of melanoma cancer cells revealed by genome-wide CRISPR-Cas9 screens Open
Background ImmTAC molecules are TCR-anti-CD3 bispecific fusion proteins that can redirect polyclonal T cell activation against tumor cells. Tebentafusp, a gp100-directed ImmTAC, is the first TCR therapeutic to demonstrate survival benefit …
View article: Diagnostic Pitfalls in Breast Cancer Pathology With an Emphasis on Core Needle Biopsy Specimens
Diagnostic Pitfalls in Breast Cancer Pathology With an Emphasis on Core Needle Biopsy Specimens Open
Context.— Breast pathology has many mimics and diagnostic pitfalls. Evaluation of malignant breast lesions, particularly in the biopsy setting, can be especially challenging, with diagnostic errors having significant management implication…
View article: Simultaneous isolation of hormone receptor–positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms
Simultaneous isolation of hormone receptor–positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms Open
Recurrent hormone receptor-positive (HR+) breast cancer kills more than 600,000 women annually. Although HR+ breast cancers typically respond well to therapies, approximately 30% of patients relapse. At this stage, the tumors are usually m…
View article: Supplementary tables from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies
Supplementary tables from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies Open
Tables 1 and 2 display estimates for height, BMI at age 18 and somatotypes for pre and postmenopausal women. Table 3 contains estimates for triple negative tumors for all four exposures.
View article: Supplementary tables from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies
Supplementary tables from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies Open
Tables 1 and 2 display estimates for height, BMI at age 18 and somatotypes for pre and postmenopausal women. Table 3 contains estimates for triple negative tumors for all four exposures.
View article: Data from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies
Data from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies Open
Height and body size in childhood and young adulthood have been consistently associated with breast cancer risk; whether associations differ across molecular subtypes is unclear. In a pooled analysis of the Nurses' Health Studies, we prosp…
View article: Data from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies
Data from Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies Open
Height and body size in childhood and young adulthood have been consistently associated with breast cancer risk; whether associations differ across molecular subtypes is unclear. In a pooled analysis of the Nurses' Health Studies, we prosp…
View article: Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Supplementary Methods
View article: Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
MRD testing results in early stage breast cancer cohort. (A) Detection limits versus the number of SNVs tracked for each cfDNA sample. (B) Comparison of fingerprint size distributions between patients that were MRD+ at any time point and t…
View article: Supplementary Data from Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Supplementary Data from Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women Open
Supplementary Figure S1; Supplementary Table S1.
View article: Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Supplementary Tables
View article: Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who experienced local recurrence only after treatment for early stage breast cancer. cfDNA time points for all patients who experienced local recurrence only. End points represent time of last follow up or death.
View article: Supplementary Table from Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
Supplementary Table from Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer Open
Supplementary Table from Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
View article: Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who were recurrence free after treatment for early stage breast cancer. cfDNA time points for all patients who did not experienced recurrence. Those marked with poor detection limits had an estimated detection limit worse than 1/1…
View article: Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Overview schematic of MRD assay. MRD assay workflow from characterizing a primary tumor to determining if a blood draw contains evidence of residual disease.